Skip to main content

Table 3 IMC outcomes stratified by the number of SIT doses

From: Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis

Covariate 1–2 doses N = 54 ≥ 3 doses N = 30 P
Multiple hospitalization, No. (%) 25 (46) 10 (33) 0.356
Failed steroid tapering after SIT, No. (%)a 13 (27) 15 (52) 0.030
Infliximab, No. (%) 49 (91) 3 (10) < 0.001
Endoscopic features, No. (%)    0.388
Ulcer 17 (49) 13 (45)  
Non-ulcerative inflammation 14 (40) 9 (31)  
Normal 4 (11) 7 (24)  
Endoscopic remission, No. (%)b 9 (64) 14 (67) 1.000
Histologic remission, No. (%)b 7 (44) 17 (71) 0.087
Infectious adverse events, No. (%) 16 (30) 9 (30) 1.000
Recurrent IMC, No. (%) 15 (28) 1 (3) 0.008
Calprotectin after SIT, mean (SD) 312 (325) 118 (138) 0.011
Mean calprotectin difference before and after SIT, (SD) 234 (204) 222 (165) 0.882
  1. aAvailable for the 79 patients who received steroids
  2. bAvailable for 40 patients
  3. Abbreviation: SIT, selective immunosuppressive therapy